. 2019 Mar 28;11(4):437. doi: 10.3390/cancers11040437

Table 1.

In vitro cytotoxicity screening of all MG analogs against A549 and H1975 NSCLC cell lines. Cells were treated with indicated compounds at 10 μM and 100 μM for 48 h, and cell viability was determined using MTT assay. Data are expressed as mean ± SEM of two independent experiments. MG derivatives exhibiting a percentage of cell viability at 10 μM (%CV_{10 µM}) <50 were defined as potent compounds.

MG Analogs	A549		H1975
MG Analogs	%CV_{10 µM}	%CV_{100 µM}	%CV_{10 µM}	%CV_{100 µM}
MG	95.31 ± 2.35	10.71 ± 0.95	77.28 ± 5.80	8.26 ± 0.79
MG1	70.55 ± 0.27	9.59 ± 1.48	40.46 ± 2.83	7.04 ± 0.22
MG2	63.57 ± 0.91	8.51 ± 0.66	28.33 ± 0.82	7.29 ± 0.57
MG3	46.90 ± 1.21	8.94 ± 0.67	17.04 ± 1.42	6.50 ± 0.28
MG4	7.93 ± 0.43	7.10 ± 0.22 ^a	23.52 ± 1.44	7.42 ± 0.55 ^a
MG5	121.54 ± 0.36	12.12 ± 1.71	44.35 ± 2.98	7.79 ± 0.12
MG6	79.56 ± 4.53	12.54 ± 1.33	20.64 ± 1.17	6.73 ± 0.15
MG7	71.84 ± 1.15	7.45 ± 0.04	27.53 ± 1.54	6.57 ± 0.25
MG8	66.59 ± 5.98	7.93 ± 0.06	20.24 ± 0.92	8.25 ± 0.32
MG9	110.92 ± 1.72	72.86 ± 3.75	89.84 ± 2.39	29.50 ± 2.80
MG10	51.00 ± 0.99	8.74 ± 0.30 ^a	27.85 ± 2.35	23.19 ± 1.38 ^a

^a The %CV was determined at 50 µM due to the low solubility of compound.